Abstract
Quinazoline scaffold has been successfully utilized for development of various inhibitors of tubulin, epidermal growth factor receptor (EGFR), polo like kinases (PLKs), Hedgehog-Gli signaling pathway and protein kinase B (PKB) /Akt pathway. Compounds based on quinazolines have shown efficacies in µM to nM range in various cancer cell lines and thus could be useful scaffolds for development of both apoptosis inducers as well as inhibitors. This compilation is based on various patents published till 2015 and divides the quinazolines in two main categories: Quinazolines as apoptosis inducers and as apoptosis inhibitors. These two main categories are further sub-categorized based on the use/pharmacological indications for these classes of patented compounds. This review will act as a tool for the researchers working on exploring the anticancer potential of quinazoline as a privileged heterocyclic. The promising anticancer profile of some of the quinazoline based compounds clearly highlights the clinical potential of this heterocycle.
Keywords: Apoptosis inducers, apoptosis inhibitors, cancer, caspases, p53, tubulin, quinazolines.
Recent Patents on Anti-Cancer Drug Discovery
Title:Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature
Volume: 11 Issue: 1
Author(s): Samir Mehndiratta, Sameer Sapra, Gurpreet singh, Manwinder Singh and Kunal Nepali
Affiliation:
Keywords: Apoptosis inducers, apoptosis inhibitors, cancer, caspases, p53, tubulin, quinazolines.
Abstract: Quinazoline scaffold has been successfully utilized for development of various inhibitors of tubulin, epidermal growth factor receptor (EGFR), polo like kinases (PLKs), Hedgehog-Gli signaling pathway and protein kinase B (PKB) /Akt pathway. Compounds based on quinazolines have shown efficacies in µM to nM range in various cancer cell lines and thus could be useful scaffolds for development of both apoptosis inducers as well as inhibitors. This compilation is based on various patents published till 2015 and divides the quinazolines in two main categories: Quinazolines as apoptosis inducers and as apoptosis inhibitors. These two main categories are further sub-categorized based on the use/pharmacological indications for these classes of patented compounds. This review will act as a tool for the researchers working on exploring the anticancer potential of quinazoline as a privileged heterocyclic. The promising anticancer profile of some of the quinazoline based compounds clearly highlights the clinical potential of this heterocycle.
Export Options
About this article
Cite this article as:
Mehndiratta Samir, Sapra Sameer, singh Gurpreet, Singh Manwinder and Nepali Kunal, Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature, Recent Patents on Anti-Cancer Drug Discovery 2016; 11 (1) . https://dx.doi.org/10.2174/1574892811666151218151506
DOI https://dx.doi.org/10.2174/1574892811666151218151506 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Connexins as Precocious Markers and Molecular Targets for Chemical and Pharmacological Agents in Carcinogenesis
Current Medicinal Chemistry Advances in Nanocarriers for Anticancer Drugs Delivery
Current Medicinal Chemistry Codon Swapping of Zinc Finger Nucleases Confers Expression in Primary Cells and <i>In Vivo</i> from a Single Lentiviral Vector
Current Gene Therapy Therapeutic Potential of Targeting PAK Signaling
Anti-Cancer Agents in Medicinal Chemistry Andrographolide Inhibits Osteopontin Expression and Breast Tumor Growth Through Down Regulation of PI3 Kinase/Akt Signaling Pathway
Current Molecular Medicine Targeting Tumor-Related Immunosuppression for Cancer Immunotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Identification of Tumor Targeting Agents by Phage Display
Medicinal Chemistry Reviews - Online (Discontinued) Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions
Current Drug Targets Working Hypothesis: Elimination of Cancer Stem Cells in Solid Tumors by Immuno-Gene Therapy Using Cancer Vaccines and Created-Inhibitory RNA
Current Cancer Therapy Reviews Cancer “Stemness”- Regulating MicroRNAs: Role, Mechanisms and Therapeutic Potential
Current Drug Targets Systemic Redox Biomarkers in Neurodegenerative Diseases
Current Drug Metabolism Mitochondria Sentencing About Cellular Life and Death: A Matter of Oxidative Stress
Current Pharmaceutical Design Recent Patents Concerning Modulators of Protein Kinase C
Recent Patents on DNA & Gene Sequences New Targets for the Modulation of Radiation Response - Selective Inhibition of the Enzyme Cyclooxygenase 2
Current Medicinal Chemistry - Anti-Cancer Agents Editorial: Smart Drug Delivery Systems (Part 1)
Current Drug Targets Minocycline and Doxycycline: More Than Antibiotics
Current Molecular Pharmacology Benzofuran Small Molecules as Potential Inhibitors of Human Protein Kinases. A Review
Current Pharmaceutical Design A Novel Gene Selection Method Based on Sparse Representation and Max-Relevance and Min-Redundancy
Combinatorial Chemistry & High Throughput Screening NOTCH Signaling as a Novel Cancer Therapeutic Target
Current Cancer Drug Targets Hypericin and its Derivatives Act as Radiosensitizing Agents That Can Inhibit Tumor Initiating Cell Viability
Clinical Cancer Drugs